Similarly, the identification of monogenic forms of diabetes has allowed for the cessation of unnecessary diabetes treatment in patients with GCK-MODY and spared patients with other forms, such as neonatal diabetes and HNF1A-MODY, from unnecessary insulin injections.7, 9 However, incorporating these advances into routine clinical care, translating them to direct benefit to patients, is challenging and can be slow. This evidence concerns the gene HNF1A and diabetes mellitus.